Drs. Ephraim Fuchs and Joseph Leventhal were among the esteemed speakers at the 6th International Sam Strober Workshop on Clinical Immune Tolerance Research, which was held March 25–26, 2024, at Oxford University’s Exeter College. This year’s event, with a focus on autoimmunity, aimed to expand the dialogue surrounding transplantation tolerance and autoimmune regulation.
Drs. Fuchs and Leventhal’s presentations provided valuable insights into ongoing trials and advancements in the field of clinical immune tolerance research, with the ultimate goal of overcoming the challenges of transplant rejection and immunosuppressive therapies.
Dr. Fuchs, Professor of Oncology and Immunology at Johns Hopkins University and a world-renowned bone marrow transplant physician and researcher, presented the results of a Phase 2, single-arm, multicenter, exploratory safety and efficacy study of IF001, a cellular therapy product, in removing long-term immunosuppression from prior living donor transplant recipients.
Dr. Leventhal, the Surgical Director of the Kidney Transplant Program at Northwestern University and a pioneer in the development of cell-based therapies to achieve tolerance induction in solid organ transplant recipients, gave a presentation on the results of clinical trials investigating transplantation tolerance through therapeutic cell transfer.
“Immune tolerance is the next frontier in providing effective long-term care to transplant recipients, said Garet Hil, Founder and CEO of the National Kidney Registry. “By bringing together leading experts like Drs. Fuchs and Leventhal at events like the International Sam Strober Workshop, we are poised to make significant strides in our understanding of immune tolerance and autoimmune regulation.”
About ImmunoFree
ImmunoFree was founded in 2023 to improve the lives of transplant patients by using new stem cell technology to eliminate the need for immunosuppressive medications without fear of organ rejection. To learn more, visit www.immunofree.com.
Back to News & Press